Table 2 First-line therapy in patients with advanced renal cell carcinoma.

From: Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: A multicenter retrospective study in Japan

 

nccRCC group

(n = 21)

cc-RCC group

(n = 165)

p

ICI + ICI (number, %)

  

0.971

Nivolumab + Ipilimumab

11 (52.4)

88 (53.3)

ICI + TKI (number, %)

  

Pembrolizumab + Lenvatinib

4 (19.0)

24 (14.5)

Pembrolizumab + Axitinib

2 (9.5)

20 (12.1)

Axitinib + Avelumab

2 (9.5)

20 (12.1)

Nivolumab + Cabozantinib

2 (9.5)

13 (7.9)

  1. Abbreviations: cc-RCC = Clear cell renal cell carcinoma; ICI = Immune checkpoint inhibitor; TKI = Tyrosine kinase inhibitor; nccRCC = Non-clear cell renal cell carcinoma.
Back to article page